Trial Profile

A clinical trial assessing LYR-210 for the treatment of CRS without nasal polyps

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 13 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mometasone (Primary)
Indications Rhinosinusitis
Focus Registrational; Therapeutic Use

Most Recent Events

13 Nov 2025 New trial record
06 Oct 2025 According to Lyra Therapeutics media release, the company plans to proceed with this additional clinical trial that was confirmed as a requirement for submission of New Drug Application (NDA) for LYR 210 for the treatment of CRS without nasal polyps, based on a September 2025 meeting with the US FDA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com